April 2016 Issue Table Of Contents

From The Editor

• If We Don’t Police Ourselves, It Will Be Done For Us

Feature Articles

• Sanofi EVP Weighs In On The Politics Of Drug Pricing
• Hot New Therapeutic MOAs Versus Neurodegenerative Diseases

The Enterprisers

• InVivo Therapeutics: Taking On Spinal-Cord Injury

Capitol Perspectives

• CMS’s Radical Experiment On Pricing Of Part B Drugs

Companies To Watch

• Osel

Inside The Industry

• Takeda CEO Mandate Sets Off A Nano Reaction
• Is Kyle Bass’ IPR Crusade Reshaping Pharma Business?
• GW Pharmaceuticals Changes Its Focus To Rare Diseases

Leadership Lessons

• How Acting With Integrity Improves Business Results

Ask The Board

• What Should Be An Area Of Focus For Clinical Trial Executives?
• How Do You Address The FDA Guidance On Integrated Summary Of Effectiveness (ISE)?
• What Are Your Top Books On Leadership And Why?